Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 98 entries
Sorted by: Best Match Show Resources per page
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Oncotarget

Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G.
PMID: 29515765
Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09.

The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN...

Cite
Montalban-Bravo G, Takahashi K, Patel K, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018;9(11):9714-9727doi: 10.18632/oncotarget.23882.
Montalban-Bravo, G., Takahashi, K., Patel, K., Wang, F., Xingzhi, S., Nogueras, G. M., Huang, X., Pierola, A. A., Jabbour, E., Colla, S., Gañan-Gomez, I., Borthakur, G., Daver, N., Estrov, Z., Kadia, T., Pemmaraju, N., Ravandi, F., Bueso-Ramos, C., Chamseddine, A., Konopleva, M., Zhang, J., Kantarjian, H., Futreal, A., & Garcia-Manero, G. (2018). Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 9(11), 9714-9727. https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo, Guillermo, et al. "Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms." Oncotarget vol. 9,11 (2018): 9714-9727. doi: https://doi.org/10.18632/oncotarget.23882
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Jan 03;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 09. PMID: 29515765; PMCID: PMC5839396.
Copy Download .nbib Format: NLM
Copy number alterations detected as clonal hematopoiesis of indeterminate potential.

Blood advances

Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA.
PMID: 29296745
Blood Adv. 2017 Jun 19;1(15):1031-1036. doi: 10.1182/bloodadvances.2017007922. eCollection 2017 Jun 27.

Recent studies have revealed that clonal hematopoiesis of indeterminate potential (CHIP) is an important risk factor for therapy-related myeloid neoplasms (t-MNs). CHIP is currently defined as a clonal hematopoietic population carrying somatic point mutations in 1 of the leukemia-associated...

Cite
Takahashi K, Wang F, Kantarjian H, et al. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv. 2017;1(15):1031-1036doi: 10.1182/bloodadvances.2017007922.
Takahashi, K., Wang, F., Kantarjian, H., Song, X., Patel, K., Neelapu, S., Gumbs, C., Little, L., Tippen, S., Thornton, R., DiNardo, C. D., Ravandi, F., Bueso-Ramos, C., Zhang, J., Wu, X., Garcia-Manero, G., & Futreal, P. A. (2017). Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood advances, 1(15), 1031-1036. https://doi.org/10.1182/bloodadvances.2017007922
Takahashi, Koichi, et al. "Copy number alterations detected as clonal hematopoiesis of indeterminate potential." Blood advances vol. 1,15 (2017): 1031-1036. doi: https://doi.org/10.1182/bloodadvances.2017007922
Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv. 2017 Jun 19;1(15):1031-1036. doi: 10.1182/bloodadvances.2017007922. eCollection 2017 Jun 27. PMID: 29296745; PMCID: PMC5728325.
Copy Download .nbib Format: NLM
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.

Leukemia

Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K.
PMID: 34876697
Leukemia. 2022 Jan;36(1):298. doi: 10.1038/s41375-021-01430-y.

No abstract available.

Cite
Oran B, Champlin RE, Wang F, et al. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022;36(1):298doi: 10.1038/s41375-021-01430-y.
Oran, B., Champlin, R. E., Wang, F., Tanaka, T., Saliba, R. M., Al-Atrash, G., Garcia-Manero, G., Kantarjian, H., Cao, K., Shpall, E. J., Alousi, A. M., Mehta, R. S., Popat, U., Futreal, A., & Takahashi, K. (2022). Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 36(1), 298. https://doi.org/10.1038/s41375-021-01430-y
Oran, Betül, et al. "Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation." Leukemia vol. 36,1 (2022): 298. doi: https://doi.org/10.1038/s41375-021-01430-y
Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan;36(1):298. doi: 10.1038/s41375-021-01430-y. PMID: 34876697.
Copy Download .nbib Format: NLM
Hematopoiesis under telomere attrition at the single-cell resolution.

Nature communications

Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S.
PMID: 34824242
Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7.

The molecular mechanisms that drive hematopoietic stem cell functional decline under conditions of telomere shortening are not completely understood. In light of recent advances in single-cell technologies, we sought to redefine the transcriptional and epigenetic landscape of mouse and...

Cite
Thongon N, Ma F, Santoni A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021;12(1):6850doi: 10.1038/s41467-021-27206-7.
Thongon, N., Ma, F., Santoni, A., Marchesini, M., Fiorini, E., Rose, A., Adema, V., Ganan-Gomez, I., Groarke, E. M., Gutierrez-Rodrigues, F., Chen, S., Lockyer, P., Schneider, S., Bueso-Ramos, C., Montalban-Bravo, G., Class, C. A., Soltysiak, K. A., Pellegrini, M., Sahin, E., Bertuch, A. A., DiNardo, C. D., Garcia-Manero, G., Young, N. S., Dwyer, K., & Colla, S. (2021). Hematopoiesis under telomere attrition at the single-cell resolution. Nature communications, 12(1), 6850. https://doi.org/10.1038/s41467-021-27206-7
Thongon, Natthakan, et al. "Hematopoiesis under telomere attrition at the single-cell resolution." Nature communications vol. 12,1 (2021): 6850. doi: https://doi.org/10.1038/s41467-021-27206-7
Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7. PMID: 34824242; PMCID: PMC8617077.
Copy Download .nbib Format: NLM
Hematopoiesis under telomere attrition at the single-cell resolution.

Nature communications

Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S.
PMID: 34824242
Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7.

The molecular mechanisms that drive hematopoietic stem cell functional decline under conditions of telomere shortening are not completely understood. In light of recent advances in single-cell technologies, we sought to redefine the transcriptional and epigenetic landscape of mouse and...

Cite
Thongon N, Ma F, Santoni A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021;12(1):6850doi: 10.1038/s41467-021-27206-7.
Thongon, N., Ma, F., Santoni, A., Marchesini, M., Fiorini, E., Rose, A., Adema, V., Ganan-Gomez, I., Groarke, E. M., Gutierrez-Rodrigues, F., Chen, S., Lockyer, P., Schneider, S., Bueso-Ramos, C., Montalban-Bravo, G., Class, C. A., Soltysiak, K. A., Pellegrini, M., Sahin, E., Bertuch, A. A., DiNardo, C. D., Garcia-Manero, G., Young, N. S., Dwyer, K., & Colla, S. (2021). Hematopoiesis under telomere attrition at the single-cell resolution. Nature communications, 12(1), 6850. https://doi.org/10.1038/s41467-021-27206-7
Thongon, Natthakan, et al. "Hematopoiesis under telomere attrition at the single-cell resolution." Nature communications vol. 12,1 (2021): 6850. doi: https://doi.org/10.1038/s41467-021-27206-7
Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7. PMID: 34824242; PMCID: PMC8617077.
Copy Download .nbib Format: NLM
Immunotherapy in Acute Myeloid Leukemia: Where We Stand.

Frontiers in oncology

Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A.
PMID: 34041025
Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021.

In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development,...

Cite
Isidori A, Cerchione C, Daver N, et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021;11:656218doi: 10.3389/fonc.2021.656218.
Isidori, A., Cerchione, C., Daver, N., DiNardo, C., Garcia-Manero, G., Konopleva, M., Jabbour, E., Ravandi, F., Kadia, T., Burguera, A. F., Romano, A., Loscocco, F., Visani, G., Martinelli, G., Kantarjian, H., & Curti, A. (2021). Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in oncology, 11656218. https://doi.org/10.3389/fonc.2021.656218
Isidori, Alessandro, et al. "Immunotherapy in Acute Myeloid Leukemia: Where We Stand." Frontiers in oncology vol. 11 (2021): 656218. doi: https://doi.org/10.3389/fonc.2021.656218
Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021. PMID: 34041025; PMCID: PMC8143531.
Copy Download .nbib Format: NLM
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.

Cancer

Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM.
PMID: 33449377
Cancer. 2021 Jun 01;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15.

BACKGROUND: New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high-risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell...

Cite
Abou Dalle I, Kantarjian HM, Ravandi F, et al. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021;127(11):1894-1900doi: 10.1002/cncr.33409.
Abou Dalle, I., Kantarjian, H. M., Ravandi, F., Daver, N., Wang, X., Jabbour, E., Estrov, Z., DiNardo, C. D., Pemmaraju, N., Ferrajoli, A., Jain, N., Wang, S. A., Jammal, N., Borthakur, G., Naqvi, K., Pelletier, S., Pierce, S., Andreeff, M., Garcia-Manero, G., Cortes, J. E., & Kadia, T. M. (2021). Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer, 127(11), 1894-1900. https://doi.org/10.1002/cncr.33409
Abou Dalle, Iman, et al. "Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission." Cancer vol. 127,11 (2021): 1894-1900. doi: https://doi.org/10.1002/cncr.33409
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 Jun 01;127(11):1894-1900. doi: 10.1002/cncr.33409. Epub 2021 Jan 15. PMID: 33449377.
Copy Download .nbib Format: NLM
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Leukemia

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U.
PMID: 34172893
Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25.

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were...

Cite
Steensma DP, Wermke M, Klimek VM, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550doi: 10.1038/s41375-021-01328-9.
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Piérola, A., Coombs, C. C., Deeg, H. J., Flinn, I., Foran, J. M., Garcia-Manero, G., Maris, M. B., McMasters, M., Micol, J. B., De Oteyza, J. P., Thol, F., Wang, E. S., Watts, J. M., Taylor, J., Stone, R., Gourineni, V., Marino, A. J., Yao, H., Destenaves, B., Yuan, X., Yu, K., Dar, S., Ohanjanian, L., Kuida, K., Xiao, J., Scholz, C., Gualberto, A., & Platzbecker, U. (2021). Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 35(12), 3542-3550. https://doi.org/10.1038/s41375-021-01328-9
Steensma, David P, et al. "Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms." Leukemia vol. 35,12 (2021): 3542-3550. doi: https://doi.org/10.1038/s41375-021-01328-9
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. PMID: 34172893; PMCID: PMC8632688.
Copy Download .nbib Format: NLM
Germline DNMT3A mutation in familial acute myeloid leukaemia.

Epigenetics

DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA.
PMID: 32856987
Epigenetics. 2021 May;16(5):567-576. doi: 10.1080/15592294.2020.1809871. Epub 2020 Aug 28.

Acute myeloid leukaemia (AML) is a heterogeneous myeloid malignancy characterized by recurrent clonal events, including mutations in epigenetically relevant genes such as

Cite
DiNardo CD, Beird HC, Estecio M, et al. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2020;16(5):567-576doi: 10.1080/15592294.2020.1809871.
DiNardo, C. D., Beird, H. C., Estecio, M., Hardikar, S., Takahashi, K., Bannon, S. A., Borthakur, G., Jabbour, E., Gumbs, C., Khoury, J. D., Routbort, M., Gong, T., Kondo, K., Kantarjian, H., Garcia-Manero, G., Chen, T., & Futreal, P. A. (2021). Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics, 16(5), 567-576. https://doi.org/10.1080/15592294.2020.1809871
DiNardo, Courtney D, et al. "Germline DNMT3A mutation in familial acute myeloid leukaemia." Epigenetics vol. 16,5 (2021): 567-576. doi: https://doi.org/10.1080/15592294.2020.1809871
DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 May;16(5):567-576. doi: 10.1080/15592294.2020.1809871. Epub 2020 Aug 28. PMID: 32856987; PMCID: PMC8078744.
Copy Download .nbib Format: NLM
Hematopoiesis under telomere attrition at the single-cell resolution.

Nature communications

Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S.
PMID: 34824242
Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7.

The molecular mechanisms that drive hematopoietic stem cell functional decline under conditions of telomere shortening are not completely understood. In light of recent advances in single-cell technologies, we sought to redefine the transcriptional and epigenetic landscape of mouse and...

Cite
Thongon N, Ma F, Santoni A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021;12(1):6850doi: 10.1038/s41467-021-27206-7.
Thongon, N., Ma, F., Santoni, A., Marchesini, M., Fiorini, E., Rose, A., Adema, V., Ganan-Gomez, I., Groarke, E. M., Gutierrez-Rodrigues, F., Chen, S., Lockyer, P., Schneider, S., Bueso-Ramos, C., Montalban-Bravo, G., Class, C. A., Soltysiak, K. A., Pellegrini, M., Sahin, E., Bertuch, A. A., DiNardo, C. D., Garcia-Manero, G., Young, N. S., Dwyer, K., & Colla, S. (2021). Hematopoiesis under telomere attrition at the single-cell resolution. Nature communications, 12(1), 6850. https://doi.org/10.1038/s41467-021-27206-7
Thongon, Natthakan, et al. "Hematopoiesis under telomere attrition at the single-cell resolution." Nature communications vol. 12,1 (2021): 6850. doi: https://doi.org/10.1038/s41467-021-27206-7
Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7. PMID: 34824242; PMCID: PMC8617077.
Copy Download .nbib Format: NLM
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.

American journal of hematology

Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H.
PMID: 34716921
Am J Hematol. 2022 Jan 01;97(1):68-78. doi: 10.1002/ajh.26395. Epub 2021 Nov 09.

The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve...

Cite
Sasaki K, Kadia T, Begna K, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2021;97(1):68-78doi: 10.1002/ajh.26395.
Sasaki, K., Kadia, T., Begna, K., DiNardo, C. D., Borthakur, G., Short, N. J., Jain, N., Daver, N., Jabbour, E., Garcia-Manero, G., Bravo, G. M., Masarova, L., Pierce, S., Konopleva, M., Ravandi, F., Tefferi, A., & Kantarjian, H. (2022). Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. American journal of hematology, 97(1), 68-78. https://doi.org/10.1002/ajh.26395
Sasaki, Koji, et al. "Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy." American journal of hematology vol. 97,1 (2022): 68-78. doi: https://doi.org/10.1002/ajh.26395
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 Jan 01;97(1):68-78. doi: 10.1002/ajh.26395. Epub 2021 Nov 09. PMID: 34716921.
Copy Download .nbib Format: NLM
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.

Leukemia & lymphoma

Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM.
PMID: 34380367
Leuk Lymphoma. 2021 Aug 12;1-9. doi: 10.1080/10428194.2021.1961235. Epub 2021 Aug 12.

Myeloid sarcoma (MS) in the setting of concomitant medullary AML is relatively well described, while much less is known about patients presenting with MS with

Cite
Abbas HA, Reville PK, Geppner A, et al. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021;1-9doi: 10.1080/10428194.2021.1961235.
Abbas, H. A., Reville, P. K., Geppner, A., Rausch, C. R., Pemmaraju, N., Ohanian, M., Sasaki, K., Borthakur, G., Daver, N., DiNardo, C., Bueso-Ramos, C., Pierce, S., Jabbour, E., Garcia-Manero, G., Konopleva, M., Ravandi, F., Kantarjian, H., & Kadia, T. M. (2021). Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leukemia & lymphoma, 1-9. https://doi.org/10.1080/10428194.2021.1961235
Abbas, Hussein A, et al. "Clinical and molecular characterization of myeloid sarcoma without medullary leukemia." Leukemia & lymphoma vol. (2021): 1-9. doi: https://doi.org/10.1080/10428194.2021.1961235
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 Aug 12;1-9. doi: 10.1080/10428194.2021.1961235. Epub 2021 Aug 12. PMID: 34380367.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 98 entries